Abstract
Rheumatoid arthritis (RA) is partly heritable; genetic and serological markers are known to confer risk of developing pathology. But given clinical heterogeneity in RA, can we predict who will develop severe disease? Substantial heritability of erosive progression rates has now been identified, but better prognostic biomarkers remain wanting.